Cecilia Catellani
Gloria Ravegnini
Chiara Sartori1
Sabrina Angelini
Maria E. Street- 1Department of Mother and Child, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy
- 2PhD Program in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy
- 3Department of Pharmacy & Biotechnology, University of Bologna, Bologna, Italy
Growth hormone (GH) and the insulin-like growth factor (IGF) system are involved in many biological processes and have growth-promoting actions regulating cell proliferation, differentiation, apoptosis and angiogenesis. A recent chapter in epigenetics is represented by microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) which regulate gene expression. Dysregulated miRNAs and lncRNAs have been associated with several diseases including cancer. Herein we report the most recent findings concerning miRNAs and lncRNAs regulating GH and the IGF system in the context of pituitary adenomas, osteosarcoma and colorectal cancer, shedding light on new possible therapeutic targets. Pituitary adenomas are increasingly common intracranial tumors and somatotroph adenomas determine supra-physiological GH secretion and cause acromegaly. Osteosarcoma is the most frequent bone tumor in children and adolescents and was reported in adults who were treated with GH in childhood. Colorectal cancer is the third cancer in the world and has a higher prevalence in acromegalic patients.
GH and IGF System
Growth hormone (GH) and the insulin-like growth factor (IGF) system consists of several components: GH, and receptor (GHR), IGF1, IGF2, Insulin-like growth factor 1 receptor (IGF1R), Insulin Like Growth Factor 2 Receptor (IGF2R), IGF binding proteins (IGFBPs), and related proteases which interact with each other and regulate several metabolic processes and body growth (1).
GH, also known as somatotropin, is produced in the anterior pituitary under the control of growth hormone releasing hormone (GHRH) which induces its synthesis and release (2, 3). Ghrelin, a peptide produced in the stomach related with nutritional stimuli, promotes also GH secretion by somatotropic cells. Conversely, GH pulsatile secretion is inhibited by somatostatin (1). In addition, GH is secreted locally by extra-pituitary tissues including neural, immune, skeletal, gastrointestinal, embryonic and reproductive tissues, exerting autocrine and paracrine roles (4). Bone and liver are important target tissues of GH, where GH binds with high affinity to the extracellular domains of GHR. This interaction leads to the phosphorylation of the tyrosine residues of the Janus kinase-2 (JAK2) which mainly activates Signal Transducer and Activator Of Transcription (STAT), Rat sarcoma protein/Extracellular signal-regulated kinase (Ras/ERK) and phosphoinositide 3-kinase/Protein kinase B/AKT Serine/Threonine Kinase (PI3K/AKT) intracellular signaling pathways (5). In the liver, GH stimulates the production of IGF1 which is a peptide hormone, that in turn regulates GH release establishing a negative feedback loop (6). IGF1 and IGF2, which belongs also to the IGF family, are produced also by many other tissues besides the liver and IGF2 is produced independent of GH stimulation (7). IGF2 mainly regulates fetal development while IGF1 increases after birth throughout growth and reduces with aging. On the target cell surface, IGF1 binds IGF1R which auto-phosphorylates and activates a signaling cascade mediated by the phosphorylation of the Insulin receptor substrate (IRS) proteins and other effectors leading to the activation of Mitogen-activated protein kinase (MAPK) and PI3K/AKT signaling pathways. Conversely, IGF2 after binding to the IGF2R does not transduce any intracellular signal. Indeed, IGF2R sequesters IGF2 from the circulation preventing its binding to the IGF1R and facilitating IGF2 degradation (8). IGF2 can bind also to the IGF1R and to the insulin receptor isoform A (IR-A) exerting its mitogen effects which have been extensively studied especially in the context of colorectal cancer (CRC) as described in a recent review (9).
The bioavailability of both IGF1 and IGF2 is controlled by a superfamily of six IGFBPs (IGFBP 1-6) characterized by a higher affinity for IGFs than IGF receptors (10). Circulating IGFs are mainly associated with IGFBP-3 and acid labile subunit, forming a ternary complex which can dissociate allowing the IGF-IGFBP complex to pass through the vessels and reach target tissues (1). The molecular structure of IGFBPs contains two homologous domains (N-terminal and C-terminal) for the IGF binding and a linker domain, which is the site for post-translational modifications and proteolysis (11). IGFBP proteolytic cleavage, which modulates IGFBP levels, is mediated by proteases belonging to three main superfamilies: serine proteases, matrix metallopeptidases (MMP), and cathepsins (8).
The GH and IGF system have growth-promoting actions regulating cell proliferation, differentiation, apoptosis and angiogenesis (1, 12, 13). Furthermore, the GH and IGF system components are also locally produced by cancer cells and exert both autocrine and paracrine roles increasing the complexity of the global framework (2). However, an involvement of GH in the development of malignancies remains unclear. Recently, it has been speculated that GH may promote neoplastic growth by contributing to create a favorable microenvironment (14). This uncertainty remains an aspect of particular importance and interest within conditions requiring GH treatment (15–18). Among these studies, a possible increased risk mainly in bone cancer is hypothesized (16, 17) whereas conditions characterized by increased GH secretion such as pituitary adenomas (gigantism/acromegaly) have an increased risk of colon cancer (19, 20).
MicroRNAs and Long Non-Coding RNAs Are Epigenetic Regulators of Gene Expression
MicroRNAs (miRNAs) are a family of small non-coding RNAs (19–25 nucleotides -nts) that can regulate a plethora of biological processes via the modulation of the expression of target genes at the post- transcriptional level (21). In particular, miRNAs bind to a specific sequence, usually localized in the 3’ untranslated regions (3’UTR) of their target mRNAs which can be either degraded or their translation can be inhibited based on sequence complementarity (22, 23). The first study identifying miRNAs as key players in human disease dates back to 2002, when Calin et al. showed that miR-15a/16-1 cluster was frequently deleted in chronic lymphocytic leukemia, and ascribed to these miRNAs a tumor suppressor role (24). After this, a growing number of reports have been published and the importance of miRNAs became clear. Tumors have a clear miRNA signature, the so-called “miRNome”, which is specific for each tumor tissue and is often associated with clinical-pathological features of the tumors (25).
MiRNAs act in a very specific, context-dependent manner, and may have a dual role both as onco-miR and tumor-suppressor miR (26). For example, miR-221 and miR-222 are important in gastrointestinal stromal tumors where they target the driver oncogene KIT, functioning as tumor suppressors. However, in other solid tumors, including glioblastoma, prostate, and breast cancer, the same miRNAs target important tumor suppressors - as Phosphatase and tensin homolog (PTEN), p27, p57 and TIMP metallopeptidase inhibitor 3 (TIMP3) - and function as oncogenic miRNAs (27–29).
Long non-coding RNAs (lncRNAs) are non-protein coding transcripts with a minimal length of 200 nts, that are important emerging gene expression regulators. Similar to miRNAs, they are involved in various biological processes including cell differentiation and apoptosis, and in pathophysiological processes as well. Numerous studies highlight that deregulated lncRNAs contribute to hallmarks of cancer including metastasis, drug resistance, and angiogenesis. lncRNAs can exert their roles through different mechanisms that can be summarized as described below (30). Mainly lncRNAs can I) act as transcription factors and modulate gene expression in space and time; II) act as a decoy and remove transcription factors and other proteins away from chromatin, preventing their normal function; III) sequester various microRNAs from mRNA targets, acting as sponges; IV) function as a guide, required for the right localization of factors (including transcription factors and chromatin modifiers) at specific sites for genome regulation; V) act as dynamic scaffolds so that cofactors can assemble together transiently (30).
MiRNAs and lncRNAs Regulating the GH/IGF1 Axis and IGF System in Cancer: Focus on Pituitary Adenoma, Osteosarcoma, and Colorectal Cancer
A recent review analyzed the current knowledge on miRNAs regulating GH, IGF1, IGF2 and IGF1R in the context of body growth (31). Here we focus on the most recent findings on miRNAs and lncRNAs regulating GH and the IGF system in the context of cancer. In particular, this review will focus on pituitary adenomas, osteosarcoma and CRC which have been documented to be related with GH treatment or GH excess as reported below. Pituitary adenomas, recently reported as pituitary neuroendocrine tumors (pitNETs) (32), are increasingly common intracranial tumors classified as somatotroph adenomas, lactotroph adenomas, corticotroph adenomas, thyrotropinomas, gonadotroph adenomas, plurihormonal adenomas, and non-functioning adenomas (33). Among these, somatotroph adenomas determine supra-physiological GH secretion and cause gigantism/acromegaly (33). The MAPK pathway and the PI3K/AKT pathway are important for pituitary tumorigenesis (34) and are activated also by the GH and IGF signaling. Osteosarcoma is the most prevalent bone malignancy in children and adolescents and is a main cause of cancer-related deaths (35). Interestingly, a recent study reported the overexpression of GHR in osteosarcoma samples and that GHR gene knockdown reduced proliferation, invasion and migration while increasing apoptosis (35). Furthermore, there is a possible increased risk of osteosarcoma in adults who were treated with GH in childhood; bone certainly represents one of the main target tissues for GH action (16, 17). Moreover, both PI3K/AKT and RAS/MAPK signaling pathways, which are key pathways for both GH and IGF signaling, were reported to be over-activated during osteosarcoma progression and metastasis (36, 37). CRC is the third most commonly diagnosed cancer in the world (38) and has a higher prevalence in acromegalic patients with respect to the general population (19). The GH/IGF1 axis and IGF system contribute to promote colorectal tumorigenesis through different mechanisms: deregulating Wnt/β-catenin signaling (39–41), reducing the responsiveness of cells to Transforming Growth Factor Beta (TGFβ) (42), enhancing the anti-apoptotic effects of both Cyclooxygenase-2 (Cox-2) (43) and Bcl2 Like 1 (Bcl-XL) (44), and enhancing the expression of the pro-angiogenetic Vascular Endothelial Growth Factor (VEGF) (45, 46). Moreover, a recent review extensively discussed the role of the activation of PI3K/AKT/mTOR Complex (mTORC) signaling pathway, and Raf/MAPK signaling pathway in the increased glucose uptake and aerobic glycolysis (Warburg effect) by CRC cells (47).
MiRNAs Regulating the GH/IGF1 Axis and IGF System in Pituitary Adenomas
Several studies concerning the involvement of miRNAs in regulating the GH/IGF1 axis and the IGF system have been conducted in GH-secreting pituitary adenomas, which are characterized by GH hypersecretion and lead to gigantism in children and acromegaly in adults (48). Table 1 summarizes the main findings of the studies investigating the role of miRNAs in pituitary adenomas. Of note, the majority of these studies refer to the involvement of miRNAs that target genes tightly related with the GH/IGF1 axis. The following findings are schematically represented in Figure 1.
Table 1 Current knowledge on the role of miRNAs and lncRNAs on the GH/IGF1 axis and IGF system in pituitary adenomas.
Figure 1 MiRNAs and lncRNAs regulating GHR and IGF signaling in pituitary adenomas. The schematic cartoon describes current knowledge relative to the interactions among miRNAs, lncRNAs and their gene targets within the GH and IGF1 signaling pathways in the context of pituitary adenoma. This figure shows that specific miRNAs and lncRNAs regulate GH and IGF signal transduction by regulating GH secretion and IGF signal transduction downstream their specific receptor. Furthermore, the effect is mediated by miRNA regulation of SSTR2 and several miRNAs are known to regulate in the nucleus the transcription of IGF2 and IGF1R. The miRNAs and lncRNAs known to interact directly with their targets are reported in red. HMGA1, High Mobility Group AT-Hook 1; PLAG1, PLAG1 Zinc Finger; IGF1, Insulin Like Growth Factor 1; IGF2, Insulin Like Growth Factor 2; IGF1R, Insulin Like Growth Factor 1 Receptor; GH, growth hormone; GHR, growth hormone receptor; SSTR2, Somatostatin Receptor 2; IRS1, Insulin Receptor Substrate 1; PTEN, Phosphatase And Tensin Homolog; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3, phosphoinositide 3-kinase; AKT1, AKT Serine/Threonine Kinase 1; mTOR, mammalian target of rapamycin; 4EBP1, Eukaryotic Translation Initiation Factor 4E Binding Protein 1; eIF4E; Eukaryotic Translation Initiation Factor 4E; SHC, Src Homology 2 Domain-Containing protein; GRB2, Growth Factor Receptor Bound Protein 2; SOS, Son of sevenless Ras/Rac Guanine Nucleotide Exchange Factor; RAS, rat sarcoma protein; RAF, Raf Proto-Oncogene, Serine/Threonine Kinase; MEK, Mitogen-Activated Protein Kinase Kinase; ERK, extracellular signal-regulated kinase; JAK, Janus Kinase; STAT, Signal Transducer And Activator Of Transcription; G-prot, G protein; AIP, Aryl Hydrocarbon Receptor Interacting Protein.
MiR-15a and miR-16-1, which belong to the same cluster of tumor suppressor miRNAs, were found to be down-regulated both in GH-secreting and prolactin-secreting pituitary adenomas (49) and were recently confirmed to be down-regulated also in pituitary tumors isolated from mice heterozygote knockout for the Menin 1 (MEN1) gene, which encodes for the tumor suppressor Menin (50). The role of miR-15a and miR-16-1 in pituitary adenomas is not fully elucidated. Interestingly, miR-16 was reported to target GHR in different cancer cell lines (51). Moreover, miR-16 may target also IGF-1, IGF1R, and IGF2R (51). The role of miR-16 in regulating the GH/IGF1 axis represents a potential key point for further investigations within pituitary adenomas.
A group of miRNAs have been found to be downregulated in GH secreting adenomas leading to the overexpression of proteins involved in pituitary tumorigenesis. Specifically, miR-34b, miR-326, miR-432, miR-548c-3p, miR-570, and miR-603, were found to be down-regulated in GH secreting adenomas leading to increased mRNA and protein levels of their target genes including High Mobility Group AT-Hook 1 (HMGA1), High Mobility Group AT-Hook 2 (HMGA2), and E2F Transcription Factor 1 (E2F1) (52). Of note, HMGA1 and HMGA2 are key proteins in the development of pituitary adenomas; indeed, they induce pituitary cell transformation through the enhancement of the activity of E2F1 and other factors (72). Furthermore, HMGA1 is a positive regulator of IGF1, IGF1R, IGFBP1 and IGFBP3 (53, 54).
A miRNA expression profiling in both sporadic GH-secreting pituitary adenomas and non-functioning pituitary adenomas highlighted that miR-107, a miRNA involved in many cancer types, was described to be upregulated. MiR-107 regulates the expression of the putative pituitary tumor suppressor gene Aryl hydrocarbon receptor-Interacting Protein (AIP) (55). Interestingly, rat pituitary adenoma GH3 cells lacking functional AIP, generated with CRISPR/Cas9 editing, showed a strong increase in GH mRNA levels and secretion, and a slight increase in cell proliferation compared to the parental GH3 cells (56). A further investigation of AIP-disrupted GH3 cells highlighted an increase in phosphorylated-STAT3 expression compared with parental GH3 cells (56). The finding is interesting as GH-induced STAT3 phosphorylation is already known to be related with GH over secretion. In addition, a further study showed STAT3 upregulation was associated with GH hypersecretion in pituitary somatotroph adenomas (73).
MiR-26b and miR-128 were found to be respectively upregulated and downregulated in GH-producing pituitary tumors (57). Specifically, miR-26b targets PTEN a key tumor suppressor which, when inactivated, leads to the activation of the PI3K/AKT pathway promoting oncogenesis. This is of note, as this pathway is also crucial in GH and IGF1 signaling (74). miR-128, targets B-lymphoma Mo-MLV insertion region 1 (BMI1) which promotes cell proliferation and tumor growth and binds to the promoter region of PTEN thereby suppressing its expression (57). This may suggest a synergistic action between these two miRNAs in contributing to tumor development, which needs further investigation.
MiR-23b and miR-130b were reported to be downregulated and to inhibit cell growth in pituitary adenomas (58). Interestingly, miR-23b targeted HMGA2, which was previously reported to regulate directly IGF2BP2 that enhances IGF2 translation (59, 60). MiR-130b targeted Cyclin A2 (CCNA2), which promotes cell cycle progression and reduces apoptosis (61).
Somatostatin receptor subtype 2 (SSTR2) was found to be increased in adenomas with respect to normal pituitaries while it was decreased in patients non-responding to treatment with long-acting Somatostatin analogues (SSAs) with respect to responders (48) and was involved in GH secretion suppression (75). In silico analysis evidenced that SSTR2 was a putative target of miR-185 and, intriguingly, miR-185 was upregulated in tumor samples from SSA non-responder adenoma patients with respect to controls while it was downregulated in the SSA responder patients (48). This suggests a possible role of this miRNA in regulating drug resistance. Subsequently, miR-185 was validated to target directly SSTR2 in GH3 cells and, consistently, the transfection of miR-185 mimics reduced the expression of SSTR2 while the use of inhibitors increased its levels (48). Furthermore, miR-185 promoted cell proliferation and reduced apoptosis in GH3 cells (48), which is compatible with a pro-oncogenic role of this miRNA in pituitary adenoma cells.
MiR-338-3p inhibition reduced both GH mRNA and protein levels in GH3 cells and reduced cell proliferation (62). Conversely, miR-338-3p overexpression did not change GH mRNA and protein levels but increased Pituitary tumor-transforming gene 1 (Pttg1) expression, a proto-oncogene which is well known to be related with pituitary adenoma development, invasiveness and recurrence (63). Furthermore, miR-338-3p overexpression reduced GHR mRNA levels as well as the expression of other genes involved in the pathogenesis of pituitary adenomas (62); however, no direct miRNA- mRNA target interactions have been proved so far, therefore further investigations are needed to clarify the role of this promising miRNA in pituitary tumorigenesis particularly concerning its relationship with Pttg1.
A recent study reported different miRNA signatures among non-functioning pituitary adenomas, prolactin-secreting pituitary adenomas and GH-secreting pituitary adenomas compared with normal pituitary glands. In particular, miR-184 was upregulated in GH-secreting pituitary adenomas (64) according to previous reported data (65). Interestingly, miR-184 was reported to inhibit cell proliferation and metastasis in human CRC cells by directly targeting IGF1R (66). This could be of interest considering its role in regulating the IGF1R in several other tumors besides GH-secreting pituitary adenomas.
MiR-21-5p is an oncomiR widely expressed in tumors including GH-secreting pituitary adenomas from acromegalic patients where it was highly expressed compared with patients with non-functioning pituitary adenomas (67). MiR-21-5p has been reported to be one of the most abundant in exosomes derived from GH-secreting pituitary adenoma and downregulated the Programmed cell death 4/Activator protein 1 (PDCD4/AP-1) pathway by targeting PDCD4 and SMAD Family Member 7 (Smad7) (67) with subsequent distant effects that have been shown in vitro, specifically osteoblast proliferation, differentiation and mineralization (67). This could represent a novel pathogenic mechanism of particular relevance, especially for acromegaly, and underlines an exosome-mediated communication between GH-secreting pituitary adenomas and both osteoblast proliferation and bone formation.
MiRNAs Regulating the GH/IGF1 Axis and IGF System in Osteosarcoma
Several miRNAs have been reported in the Literature to have a role in the regulation of the GH/IGF1 axis and IGF system in osteosarcoma (Table 2). The following findings are schematically represented in Figure 2.
Table 2 Current knowledge on the role of miRNAs and lncRNAs on the GH/IGF1 axis and IGF system in osteosarcoma.
Figure 2 MiRNAs and lncRNAs regulating IGF signaling in osteosarcoma. The schematic cartoon describes current knowledge relative to the interactions among miRNAs, lncRNAs and their targets within the IGF1 signaling pathways in the context of osteosarcoma. The miRNAs and lncRNAs known to interact directly with their targets are reported in red. IGF1, Insulin Like Growth Factor 1; IGF2, Insulin Like Growth Factor 2; IGF1R, Insulin Like Growth Factor 1 Receptor; IRS1, Insulin Receptor Substrate 1; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3, phosphoinositide 3-kinase; AKT1, AKT Serine/Threonine Kinase 1; mTOR, mammalian target of rapamycin; SHC, Src Homology 2 Domain-Containing protein; GRB2, Growth Factor Receptor Bound Protein 2; SOS, Son of sevenless Ras/Rac Guanine Nucleotide Exchange Factor; RAS, rat sarcoma protein; RAF, Raf Proto-Oncogene, Serine/Threonine Kinase; MEK, Mitogen-Activated Protein Kinase Kinase; ERK, extracellular signal-regulated kinase.
MiR-26a was described to be downregulated in osteosarcoma tissues with respect to adjacent normal tissues (76). Consistently, in vitro experiments using miRNA mimics and inhibitors evidenced that miR-26a overexpression determined a reduction in cell proliferation whereas miRNA inhibition increased cell proliferation. In vivo experiments in mice highlighted that the transplantation of osteosarcoma cells stably overexpressing miR-26a, suppressed tumor growth (76). In line with these findings, injection of miR-26a knocked-down osteosarcoma cells in these mice promoted an increase in tumor growth. Thus, miR-26a could be described as a tumor-suppressive miRNA in osteosarcoma and, interestingly, IGF1 was shown to be a direct target of miR-26a (76).
As reported in the following lines, it is noteworthy that the majority of the studies available in the Literature concerning miRNAs, the GH/IGF1 axis and the IGF system in osteosarcoma are focused on miRNAs that target, both directly or indirectly, the IGF1R both in vivo and in vitro. In particular, miR-16 was reported to be downregulated in osteosarcoma cell lines and tissues (77). MiR-16 overexpression reduced cell proliferation in vitro and tumor growth in mice by targeting directly the IGF1R with subsequent inhibition of the Raf1- Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2)-ERK1/2 pathway (77). Interestingly, miR-16 was reported also as downregulated in pituitary adenomas (49). Based on these evidences, one could speculate that miR-16 overexpression could represent a potential therapeutic approach for osteosarcoma, and maybe also for pituitary adenomas.
Similar results were described for miR-100 also, which expression was significantly reduced in osteosarcoma tissues and cell lines (78); the role of miR-100 was investigated generating stable cell lines overexpressing this miRNA and through the subsequent observation of reduced proliferation, invasion and migration. In addition, miR-100 was shown to target directly the IGF1R and to inhibit PI3K/AKT and MAPK/ERK pathways. Interestingly, miR-100 overexpression also increased cell sensitivity to cisplatin and this should be taken into account since cisplatin resistance is one of the major issues in osteosarcoma treatment.
A further study showed decreased miR-133a in osteosarcoma cell lines, and this miRNA was shown to control cell proliferation, migration and invasion in vitro, and growth and metastasis in vivo (79). Specifically, the in vitro experiments showed that miR-133a overexpression decreased cell proliferation, invasion and migration. The injection of osteosarcoma transfected cells into nude mice both subcutaneously, and systemically decreased tumor size, and the number of lung and liver metastases, respectively. Silencing of IGF1R exerted effects similar to miR-133a overexpression suggesting that the tumor suppressive function of miR-133a could depend on the regulation of the IGF1R gene (79). Moreover, IGF1R was validated as a direct target of miR-133a and the ERK/AKT signaling pathway was affected also. The further impact of miR-133a on osteosarcoma progression in vivo strongly encourages further studies to evaluate whether it could be a new prognostic biomarker and a possible anti-metastatic target for osteosarcoma treatment.
MiR-503 was described also to be significantly downregulated both in osteosarcoma tissues and cell lines when compared to matched adjacent non-tumorous tissue and normal osteoblast cells, respectively (80). A thorough analysis showed that miR-503 overexpression inhibited significantly proliferation and invasion and decreased IGF1R protein levels. IGF1R was subsequently identified as a putative target of miR-503 via bioinformatic analysis and, then experimentally validated via western blot analysis and luciferase assay. The direct interaction between miR-503 and IGF1R was further confirmed by transfecting overexpressing miR-503 cells with an IGF1R plasmid. The increased IGF1R protein determined a significant increase in proliferation and invasion, further confirming the anti-proliferative and anti-invasive effects of this miRNA. Consistently, an inverse correlation between miR-503 and IGF1R levels was identified in osteosarcoma tissues (80). This study evidenced also that miR-503 levels were lower in osteosarcoma advanced stages compared with initial stages, and this could be helpful in the future to discriminate between different tumor stages also in clinical practice.
A recent investigation reported that a further miRNA, miR-302a, was reduced both in osteosarcoma tissues and cell lines, and a reduction in its expression levels was observed also in metastatic tissues (81). In vitro, the overexpression of this miRNA reduced migration and invasion of osteosarcoma cells transfected with a miRNA mimic. IGF1R was validated as a target gene for miR-302a and consistently, IGF1R silencing determined similar effects as miR-302a overexpression (81). This investigation highlighted also that miR-302a suppressed osteosarcoma metastases through targeting IGF1R, and this may provide a novel target to prevent metastasis in osteosarcoma patients.
The most recent study described a decreased expression of miR-939 in osteosarcoma tissues which correlated also with clinical stage and the presence of distant metastases in patients (82). Patients with low miR-939 expression showed decreased overall survival compared with patients with high miR-939 expression. Overall, the data ascribed to miR-939 a role of tumor suppressor, which was confirmed in additional functional experiments performed in osteosarcoma cell lines; the restoration of miR-939 expression inhibited proliferation, migration and invasion while increased apoptosis was observed in vitro, and reduced tumor growth and weight in vivo (82). Bioinformatic analysis identified IGF1R as a putative target for miR-939, which was further confirmed via luciferase assay in cell lines and supported by the observation of an inverse correlation between miR-939 and IGF1R levels in osteosarcoma tissues. The authors showed also that miR-939 overexpression downregulated PI3K-AKT pathway downstream the IGF1R and the restoration of miR-939 could represent a potential therapeutic approach for patients with osteosarcoma following the purpose of a miRNA-based targeted anticancer therapy.
All these studies highlight that IGF1R is a common target of most of the miRNAs studied in the context of osteosarcoma and this confirms also the complexity of the miRNA network in the regulation of gene expression. Interestingly, all these studies have reported only downregulation of specific miRNAs which lead to an increased expression of IGF1R in osteosarcoma. However, the evaluation of other targets within the GH/IGF1 axis and the IGF system would be of paramount importance to clarify the implications of miRNAs in osteosarcoma development and to identify new possible therapeutic targets.
MiRNAs Regulating the GH/IGF1 Axis and IGF System in Colorectal Cancer
CRC is one of the most commonly diagnosed malignancies and several studies have investigated the role of miRNAs on the GH/IGF1 axis and IGF system in CRC. The findings are summarized in Table 3 and schematically represented in Figure 3.
Table 3 Current knowledge on the role of miRNAs and lncRNAs on the GH/IGF1 axis and IGF system in colorectal cancer.
Figure 3 MiRNAs and lncRNAs regulating IGF signaling in colorectal cancer. The schematic cartoon describes current knowledge relative to the interactions among miRNAs, lncRNAs and their targets within the GH and IGF1 signaling pathways in the context of colorectal cancer. The miRNAs and lncRNAs known to interact directly with their targets are reported in red. HMGA1, High Mobility Group AT-Hook 1; PLAG1, PLAG1 Zinc Finger; PLAGL2, PLAG1 Like Zinc Finger 2; IGF1, Insulin Like Growth Factor 1; IGF2, Insulin Like Growth Factor 2; IGF1R, Insulin Like Growth Factor 1 Receptor; IRS1, Insulin Receptor Substrate 1; PIK3R1, Phosphoinositide-3-Kinase Regulatory Subunit 1; PIK3, phosphoinositide 3-kinase; AKT1/2, AKT Serine/Threonine Kinase 1/2; mTOR, mammalian target of rapamycin; SHC, Src Homology 2 Domain-Containing protein; GRB2, Growth Factor Receptor Bound Protein 2; SOS, Son of sevenless Ras/Rac Guanine Nucleotide Exchange Factor; RAS, rat sarcoma protein; RAF, Raf Proto-Oncogene, Serine/Threonine Kinase; MEK, Mitogen-Activated Protein Kinase Kinase; ERK, extracellular signal-regulated kinase.
One of the first studies identified a signature of 130 miRNAs differentially expressed in CRC tissue samples with respect to normal tissue. Moreover, the expression was described to change depending on the tumor stage (86). Among these, 19 miRNAs were found to be downregulated at tumor stages II, III, and IV (Table 3), while miR-21 was upregulated. MiR-138, miR-143, miR-145, miR-150, miR-192, miR-194, miR-202, miR-320, miR-382, miR-503, miR-519e-5p and miR-526c were described as downregulated in all CRC stages. Interestingly, 94 of these miRNAs targeted genes within the IGF1R signaling pathway, among these IGF1R, IRS-1, AKT, Glycogen Synthase Kinase 3 (GSK3) α/β, MEK1, ERK 1/2, p38, p70, p90, Activating Transcription Factor (ATF)-2, and c-Jun N-terminal kinase (JNK). The analysis of the phosphorylation status of these targeted molecules in the different CRC stages showed increased activation leading to the identification of the IGF system as a key regulator in CRC progression (86). Of note, the cluster miR-143/145 was further reported to target directly the IGF1R in CRC cells, and provided evidence of a cooperative repression of the IGF1R gene expression by the two miRNAs (87). Furthermore, the authors showed that miR-143/145 inhibited CRC cell proliferation in vitro, by inhibiting IGF1R expression highlighting their tumor suppressor activity in CRC, the importance of IGF1R in CRC pathogenesis, and underlying a novel regulatory network to fine-tune cell proliferation (87). In view of these considerations, a combined treatment with both miR-143/145 could represent a strategy to restore their levels in those cancers which exhibit a downregulation, to restore their functions.
A further study identified a group of 77 miRNAs that were differentially expressed between early and late time points of inflammation and tumor growth in a mouse model of colitis-associated cancer, histologically and molecularly similar to human CRC (88). Interestingly, an in silico analysis highlighted that these miRNAs were predicted to target genes involved in the PI3K/AKT and IGF1 signaling cascades. Among these 77 miRNAs, 24 were reported to be differentially expressed in human CRC also (Table 3), highlighting that the identified signature was relevant for human disease (88). Among these miRNAs, miR-223, the most strongly upregulated miRNA in the mouse model, was further investigated in CRC cell lines. This study showed that miR-223 could target directly the IGF1R thus regulating the PI3K/AKT pathway (88). Another miRNA among these, miR-139-5p, was previously described as one of the most downregulated miRNAs in CRC tissues, and in vitro studies demonstrated that miR-139-5p overexpression led to a remarkable reduction in CRC cell migration and invasion, without affecting cell proliferation (89). Consistently, miR-139-5p was shown to be able to suppress the formation of tumor metastasis in nude mice (89). In silico analyses identified IGF1R as a relevant target of miR-139-5p, and was subsequently validated. As expected, miRNA overexpression determined a reduction in IGF1R expression and an inhibition in MEK/ERK/Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signal transduction which is involved in MMP-2 transcription regulation. These miRNAs and especially miR-223 which are involved in PI3K/AKT, IGF1, and MEK/ERK/NF-κB signaling cascades could represent a molecular link between inflammation and cancer. This aspect should be further investigated to clarify whether carcinogenesis could be triggered by inflammation-induced miRNAs. Moreover, these findings suggested that miR-139/IGF1R regulation was involved in the control of invasive and metastatic capabilities of tumor cells.
A screening of 939 miRNAs highlighted, with respect to the above profiling studies, the downregulation of miR-195 and miR-497 and the upregulation of miR-424 in CRC tissues with respect to non-cancerous mucosa (90). These results were confirmed in vitro in CRC cell lines observing reduced proliferation, cell survival, migration and invasion. These three identified miRNAs belong to a cluster of miRNAs (miR-15/16/195/424/497) predicted to target IGF1R. The authors showed that only miR-497 targeted directly the IGF1R. Consistently, mir-497 overexpression inhibited also PI3K/AKT downstream the receptor (90). Reduced ERK activation was also detected suggesting a role of miR-497 in MEK/ERK signaling (90). This highlights the importance of miR-15/16/195/424/497 cluster also in the context of CRC besides pituitary adenoma and osteosarcoma, which were previously described. Moreover, the downregulation of miR-195 and miR-497 and the upregulation of miR-424 in CRC tissues seem to be early events in CRC development, and thus could be studied as potential biomarkers for CRC diagnosis. Furthermore, the restoration of miR-497 levels could be studied as a potential strategy to inhibit IGF1R in CRC.
An additional miRNA identified as having a tumor suppressor role in CRC was miR-184, which levels were reduced in both CRC tissues and cell lines (66). Experimental investigations using miR-184 mimic, showed that the overexpression of miR-184 in CRC cell lines inhibited cell proliferation, migration and invasion. Bioinformatics and laboratory analyses validated IGF1R as a direct target of miR-184. Consistently, IGF1R small interfering RNAs reproduced the actions of miR-184 in CRC (66). MiR-184 could be further investigated as a potential target for CRC treatment due to its role in the regulation and inhibition of IGF1R expression.
A recent study showed that KRAS-mutated CRC cells activated IGF1R expression via a novel MEK-DNMT1 signaling pathway involving miR-137 (91). MiR-137 was silenced in both cell lines and tissues indicating that it could act as a tumor suppressor, and its silencing represented an early event during colorectal carcinogenesis (91, 110). In particular, the study by Chu et al. highlighted that KRAS mutation increased IGF1R expression at both the mRNA and protein levels through Y-box-binding protein-1 (YB-1) upregulation which was then validated as a miR-137 target gene. YB-1 is a protein involved in the regulation of genes related with tumor progression. In vivo, miR-137 expression was found to be reduced in CRC liver metastases from KRAS-mutated CRC patients, whereas YB-1 and IGF1R were upregulated, confirming the previous data. Furthermore, miR-137 levels were negatively correlated with YB-1 levels, and YB-1 and IGF1R were positively correlated (91). The involvement of miR-137 in the regulation of MEK signaling could open the view for the use of this miRNA as a MEK inhibitor in combination with chemotherapy in patients with KRAS mutant tumors in order to prevent the recurrence of colorectal liver metastases.
Among the deregulated miRNAs in CRC, also miR-532 had a tumor-suppressive role (92). Song et al. showed that miR-532 was downregulated in both CRC tissues and cell lines compared to adjacent normal tissues and normal human colon epithelium, respectively. Further analyses showed that its overexpression inhibited cell proliferation, migration, invasion, colony formation and promoted apoptosis in vitro, while reduced tumor growth was observed in vivo (92). The authors showed through a luciferase assay that miR-532 targeted directly IGF1R and, consistently, miR-532 expression levels were negatively correlated with IGF1R levels in CRC tissues. Furthermore, IGF1R silencing mimicked the tumor-suppressive effects of miR-532 in CRC cells, further confirming its direct interaction with IGF1R, and miR-532 overexpression inhibited PI3K/AKT pathway activation both in vitro and in vivo (92). MiR-532 could be a possible non-invasive diagnostic tool due to the specificity of its expression in CRC, and its role in the regulation of IGF1R could offer also an opportunity for CRC treatment.
The let-7 family has been reported to be downregulated in many types of cancer, including CRC (111). IGF1R has been predicted to be a direct target of let-7 miRNAs, and among this family, let-7e had the highest probability score (93, 94). In particular, the study by Samadi et al. showed that let-7e overexpression induced a reduction in IGFR protein content, suppressed growth arresting the cell cycle in the G1 phase, and increased apoptosis. Similar results were reported by Li et al. who showed a reduction in phospho-AKT which is part of the IGF1R signaling pathway (93). In addition, the authors identified IGF1 as one of the predicted targets of the let-7 family, including let-7e. Intriguingly, the treatment of CRC cells with IGF1 reduced let-7e levels, highlighting a negative feedback regulation between let-7e and IGF1/IGF1R signaling (93). This negative feedback regulation could be of great interest in IGF1R-targeted therapeutic strategies in CRC.
Several studies have provided sufficient evidence that miR-9 also participates in colorectal tumorigenesis acting as a tumor suppressor (112, 113). A recent study described a reduction in miR-9 expression in CRC cell lines under high glucose concentrations (95). In particular, miR-9 downregulation due to increased glucose concentration, was associated with increased cell proliferation, epithelial-to-mesenchymal transition (EMT), migration and invasion. It is noteworthy that, when CRC cells were transfected with miR-9 mimic, they expressed less phospho-IGF1R, cyclin B1, and N-cadherin, all involved in cell cycle progression while E-cadherin expression was increased; this latter is involved in cell-cell adhesion and tumor suppression (95). This study suggests that hyperglycemia can modulate tumorigenesis in a way that can be mediated by miR-9 and the control of blood glucose concentrations could serve as an adjuvant potential strategy for CRC treatment.
The newly discovered GATA4-miR1 was located in the second intron of the GATA4 gene, which belongs to a transcription factor family involved in carcinogenesis (96). Bioinformatic tools and experimental research identified IGF1R, AKT1 and AKT2 genes as GATA4-miR1 targets. Consistently, GATA4-miR1 overexpression led to a significant reduction in IGF1R and AKT1/2 expression levels in several cell lines, including the CRC SW480 line. Moreover, a luciferase reporter assay documented a direct interaction between this miRNA and the target genes. GATA4-miR1 overexpression in the CRC cell line determined an increase in the sub-G1 cell cycle population, and a reduction in cell survival and proliferation (96). This newly discovered miRNA warrants further investigation in particular within the context of cell cycle progression and cell proliferation in order to establish whether it could have a therapeutic potential in CRC.
A recent review summarized a number of miRNAs related with IGF2 regulation in CRC (9). MiR-675 and its precursor, the lncRNA H19, were overexpressed in CRC cell lines and tissues suggesting that they might play a role in CRC tumorigenesis. Functional analysis showed that miR-675 downregulated tumor suppressor Retinoblastoma (RB) which controls proliferation and malignant transformation (97). H19 was described to be located close to the IGF2 locus (98) and miR-675 was further reported to target directly the IGF1R in placentas (99). The cross-talk highlighted in this study underlines a relationship between the lncRNA H19 and miR-675 in the pathogenesis of CRC, and underlines the importance of further investigation of the role of lncRNAs and miRNAs in the context of CRC. A further study reported a simultaneous increase in miR-483-3p, miR-483-5p and IGF2 in CRC tissues compared with controls (100). Intriguingly, the authors showed undetectable promoter activity upstream miR-483, which is located within intron 7 of the IGF2 gene. Therefore, it was hypothesized that miR-483 could be co-transcribed with IGF2 due to the lack of a promoter of its own and its overexpression could contribute to the pro-oncogenic effect attributed to IGF2 (100). The authors subsequently proved that miR-483-3p overexpression increased cell proliferation targeting directly DLC-1 which is a tumor suppressor involved in many types of cancer (100). Moreover, from a translational point of view, miR-483-5p could be a feasible biomarker for CRC screening due to the fact that it can detect CRC with an acceptable specificity and sensitivity in serum. A more recent study highlighted that miR-486-5p was downregulated in CRC tissues and cell lines due to higher DNA methylation of its promoter (101). MiR-486-5p overexpression suppressed cell proliferation and motility in vitro and reduced growth velocity and weight of tumors and tumor nodule formation in vivo. The investigation of the molecular mechanisms underlying these effects showed that miR-486-5p acts as a tumor suppressor by targeting the transcription factor PLAG1 Like Zinc Finger 2 (PLAGL2) which regulates IGF2 and β-catenin expression, thus resulting in the inhibition of cell proliferation and invasion (101). This study highlighted the importance of another epigenetic mechanism, DNA methylation, in the regulation of miRNA transcription which in turn regulate gene expression; this interplay warrants further investigation. Moreover, this study reported increased levels of plasma miR-486-5p in CRC which was tumor derived suggesting it might be explored as a novel prognostic and diagnostic biomarker of CRC. In a specific subtype of CRC, characterized by microsatellite instability, miR-181a, miR-135a and miR-302c were all downregulated in tissue samples and cell lines with respect to microsatellite stable samples (102). MiRNA downregulation was mainly due to the hypermethylation of the CpG island in the promoter region of these miRNAs. The evaluation of their biological functions revealed that they acted as tumor suppressors thereby reducing cell growth and promoting apoptosis. Using a luciferase reporter assay, the authors confirmed that miR-181a, miR-135a and miR-302c targeted directly PLAG1 which is an IGF2 transcription factor (102). The pro-oncogenic action of PLAG1 was mainly mediated by the IGF2 signaling pathway (114), and IGF2 expression was markedly reduced by miR-181a, miR-135a and miR-302c overexpression (102). Interestingly, the restoration of these miRNAs could increase sensitivity to 5-fluorouracil and this should be taken into account in CRC treatment. The most recent study reported that miR-491-5p was downregulated in both CRC tissues and cell lines and its overexpression reduced proliferation in vitro and tumor growth in vivo (103). Functional analysis demonstrated that miR-491-5p overexpression exerted a tumor suppressor effect by targeting IGF2, and this was also confirmed by the negative correlation between miRNA levels and IGF2 mRNA and protein levels in CRC tissues and cell lines. The miR-491-5p/IGF2 interaction was also confirmed by the finding that IGF2 overexpression partially reverted the anti-tumor effects of miR-491-5p (103). Moreover, this study showed that plasma miR-491-5p was reduced in CRC patients, and thus could have a diagnostic potential in CRC as it can identify CRC with high sensitivity and specificity.
LncRNAs Regulating the GH/IGF1 Axis and IGF System in Pituitary Adenomas
A recent review summarized the lncRNAs that have been involved in the pathogenesis of pituitary adenomas (115). The findings are summarized in Table 1 and schematically represented in Figure 1. Among these, two studies reported the involvement of the lncRNA H19, an imprinted oncofetal gene, which is aberrantly expressed in cancer tissues (98), and in pituitary adenomas (68, 69). In particular, the study by Lu et al. reported that H19 was highly expressed in GH-secreting invasive pituitary adenomas with respect to non-invasive GH-secreting adenomas (69). The study by Wu et al., evidenced that the lncRNA H19 was downregulated also in tissues from different pituitary tumor subtypes with respect to normal pituitary gland; additionally, its levels were negatively correlated with the tumor volumes (68). Further investigations showed that H19 overexpression inhibited proliferation and colony formation in vitro, and reduced xenografts tumor burden in vivo. The authors attempted also to elucidate the underlying mechanisms highlighting that H19 directly interacted with the Eukaryotic Translation Initiation Factor 4E Binding Protein 1 (4E-BP1), at the TOS motif inhibiting competitively its binding to Raptor. Overall, this disruption inhibited the recruitment of mTORC1 required for mTOR signaling (68) which is needed for the final protein synthesis induced by GH which requires 4E-BP1 and S6 phosphorylation (116). These investigations highlighted the importance of lncRNA H19 to study the invasion capacity of GH-secreting pituitary adenomas but also that it could be used as a potential biomarker of diagnosis and prognosis.
Two studies have reported the involvement of the lncRNA MEG3 in the development of GH-secreting pituitary adenomas (70, 71). LncRNA MEG3 is encoded by a maternally imprinted gene and suppresses cell proliferation (117). In particular, the study by Mezzomo et al. highlighted a higher expression of MEG3 in GH-secreting pituitary adenomas with respect to non-functioning pituitary adenomas, where the expression was lost in most samples (70). Consistently, the study by Tang et al. reported that MEG3 levels were increased in GH-secreting pituitary tumors with respect to non-functioning pituitary tumors (71). Moreover, the authors reported that MEG3 levels were positively correlated with GH and IGF1 serum levels, whilst they were negatively correlated with tumor size. Interestingly, MEG3 levels were significantly increased in the Gsp-mutated group compared to the non-mutated one, and determined a reduction in tumor proliferation and invasiveness. Gsp is an oncogene which promotes the phosphorylation of cAMP responsive element binding (CREB) and may lead to GH hypersecretion. The proposed mechanism involves Gsp which enhances MEG3 expression by means of phospho-CREB overexpression leading to a reduction in cell proliferation and invasiveness. Indeed, a cAMP responsive element is located at the MEG3 proximal promoter region and is critical for MEG3 activity (71). This study reveals a new possible pivotal gene in the development of pituitary tumors, and this could be useful in the development of novel therapeutic strategies against pituitary adenomas. However, the mechanism underlying the putative tumor suppressive role of MEG3 in GH-secreting pituitary adenomas needs further investigation.
LncRNAs Regulating the GH/IGF1 Axis and IGF System in Osteosarcoma
To the best of our knowledge only three studies have described the role of lncRNAs targeting the GH/IGF1 axis and the IGF system in osteosarcoma. However, these studies which are summarized in Table 2 and schematically represented in Figure 2, have certainly paved the way to further investigations.
The first study reported in the Literature identified the lncRNA NNT-AS1 (83). In particular, its overexpression increased cell proliferation, survival and motility in vitro and tumor formation in vivo. Accordingly, NNT-AS1 knockdown determined opposite effects and increased apoptosis. The authors demonstrated that NNT-AS1 acted by sponging miR-320a thereby increasing the expression of osteosarcoma-promoting genes including IGF1R. Consistently, IGF1R protein levels were increased in osteosarcoma cells overexpressing NNT-AS1, while it was decreased after NNT-AS1 knockdown. Furthermore, functional analyses clearly showed that NNT-AS1 effects could be attenuated by miR-320a overexpression (83). The network above including the lncRNA NNT-AS1, miR-320a and its targets, could be of interest to develop new therapeutic strategies for osteosarcoma treatment.
A recent study reported that the expression of the lncRNA SNHG12 was increased in osteosarcoma cell lines (84). In nude mice, the silencing of this lncRNA reduced tumor weight and volume, and functional analysis showed that lncSNHG12 downregulation suppressed osteosarcoma cell growth via the regulation of the miR-195-5p/IGF1R axis. In particular, lncSNHG12 downregulation reversed IGF1R-induced metastases and proliferation in osteosarcoma cells. IGF1R was shown to be a direct target of miR-195-5p that was sponged by lncSNHG12 (84). The identification of the lncRNA SNHG12/miR-195-5p/IGF1R axis underlines the importance of lncRNA SNHG12 in the regulation of tumor progression, and could an interesting way to inhibit osteosarcoma progression and metastases.
In the same year, Fei et al. showed that lncRNA AFAP-AS1 was upregulated in osteosarcoma both in tissues and cell lines (85). Functional evaluation highlighted that AFAP-AS1 knockdown significantly inhibited proliferation, colony formation, suppressed migration and invasion and increased apoptosis in vitro. Consistently, AFAP-AS1 knockdown inhibited tumorigenesis in vivo. A further deepening of the molecular mechanisms identified miR-497 as a direct downstream target of AFAP-AS1. IGF1R was a predicted target of miR-497, and the authors showed that IGF1R negatively correlated with miR-497 and correlated positively with AFAP-AS1 expression in osteosarcoma tissues. Therefore, AFAP-AS1 exerted tumor-promoting actions regulating IGF1R expression by sponging miR-497 (85). The possible role of AFAP-AS1 as a proto-oncogene could represent a promising therapeutic target for osteosarcoma.
LncRNAs Regulating the GH/IGF1 Axis and IGF System in Colorectal Cancer
Recent studies agreed in identifying lncRNA dysregulation as a critical modulator of CRC progression; these findings are summarized in Table 3 and schematically represented in Figure 3.
The lncRNA CRNDE was identified for the first time by Graham et al. who described it to be upregulated in colorectal adenomas and CRC (118). A further study evidenced that the lncRNA CRNDE was regulated by insulin and IGFs, and suggested that CRNDE nuclear transcripts, generated from CRNDE by alternative splicing, played a role in controlling CRC cell metabolism (104). In detail, nuclear CRNDE transcripts were downregulated in CRC cell lines after treatment with insulin, IGF1 and IGF2. PI3K/AKT/mTOR and Raf/MAPK pathways are the main signaling pathways for insulin, IGF1 and IGF2; functional studies showed that CRNDE knockdown affected the expression of genes strongly related with insulin/IGF signaling. Overall, the findings highlighted a feedback regulatory mechanism between CRNDE and insulin/IGF signaling in CRC (104). From a translational point of view, CRNDE transcripts, which are upregulated in early precancerous stages, could be useful as potential diagnostic biomarkers both in tissue and plasma to detect early cancerous tissue degenerations.
A further lncRNA linked to IGF regulation was H19. As previously described, H19 and IGF2 genes are located on the same chromosome (11p15.5), and share the same imprinting regulatory regions (119). Several studies showed that H19 acts as an oncogene in various cancers, including CRC and its upregulation predicts poor prognosis in patients with CRC (120). In particular, its role in CRC was investigated in five recent studies and they all reported H19 upregulation (105, 106, 120–122). However, the exact mechanism through which H19 exerts its action has not been completely understood. According to Han et al., H19 could control the expression of cell-cycle regulatory genes including cyclin D1, cyclin E1, and Cyclin Dependent Kinase 4 (CDK4) by combining with the Eukaryotic Translation Initiation Factor 4A3 (eIF4A3) and hampering the recruitment of eIF4A3 to their transcripts, thus accelerating cell-cycle progression and CRC proliferation (105). A further study identified that the H19/miR-138/HMGA1 axis was implicated in the regulation of migration and invasion in CRC (106). In detail, the authors demonstrated that H19 promoted cell proliferation, migration and invasion in vitro and tumor growth and metastases in vivo by sponging miR-138 thereby increasing the expression of HMGA1 (106). As previously reported, HMGA1 is a positive regulator of several proteins belonging to the IGF system (53, 54). Most importantly, the involvement of H19 in the promotion of cell migration and invasion evidenced a potential new treatment option for CRC.
It is well known that eukaryotic genomes are transcribed in both sense and antisense directions, producing abundant levels of noncoding RNAs (107). Among these, IGF2-AS was reported as an antisense lncRNA for the IGF2 gene (108). Interestingly, the authors found that IGF2-AS was overexpressed in CRC cell lines and regulated the expression of specific genes by competitive sponging of miR-150 and miR-193b. Remarkably, IGF2BP3 that increases IGF2 translation, was identified among the predicted target genes for miR-150. In the same year, Zhang et al., by using the CRC Cancer Genome Atlas (TCGA) database, reported a negative correlation between IGF2-AS and the overall survival of CRC patients. Similarly, the analysis of 521 samples (480 tumor tissue and 41 adjacent non-tumor tissue samples) extracted from the TCGA database highlighted that IGF2-AS expression was upregulated in CRC and correlated negatively with distant metastases (121). Thus, the lncRNA IGF2-AS could represent a possible prognosis-related biomarker of CRC. The whole transcriptome sequencing of both early-stage and late-stage CRC tissues highlighted key lncRNAs associated with CRC (109). In particular, the authors validated the downregulation of the lncRNA KIAA0125 and MSTRG.35002 both in early- and late-stage CRC tissues compared with normal colon (109). Of note, functional enrichment analysis found that KIAA0125 was significantly enriched in PI3K/AKT signaling pathway which is pivotal in both GH and IGF signaling.
Summary and Perspectives
This review highlights the role for miRNAs and lncRNAs in regulating genes related with GH and IGF signaling in the context of cancer. In particular, we focused on the role of miRNAs and lncRNAs in pituitary adenomas, osteosarcoma and CRC, which are known to be tightly related with GH and the IGF system. Both miRNAs and lncRNAs are involved in the regulation of gene expression, the former by directly regulating gene expression, the latter by sponging miRNAs and/or acting less frequently as antisense transcripts. This opens the way to an increasingly more complicated but also more comprehensive regulatory network that needs to be further studied both within tumors per se, and as a regulatory process that can be modified by treatments, requiring the use of GH, and IGF1. To date many studies have reported several miRNAs potentially involved in the modulation of the GH and IGF signaling networks, however, it is still difficult to identify the key players of this complex landscape. Novel potential therapeutic targets emerge based on the deregulated non-coding RNAs and their regulated genes, which warrant further research. In particular, miR-15/16/195/424/497 cluster appears to be of pivotal importance for both pituitary adenoma, osteosarcoma, and CRC, thus it should be further explored. Additionally, several miRNAs emerged as potential therapeutic targets, diagnostic biomarkers, and treatment sensitizers. Moreover, lncRNA-H19 is emerging both in pituitary adenomas and CRC as a promising diagnostic and prognostic marker. Most of the studies within these cancers have currently focused mainly on IGF1R, however, the entire GH/IGF1 axis and IGF system should be studied in order to obtain a comprehensive picture within tumors.
Author Contributions
Conceptualization: MS and CC. Writing-original draft preparation: CC, GR, and SA. Writing-review & editing: SA, CC, CS, and MS. Visualization: CC and GR. Supervision: MS. All authors contributed to the article and approved the submitted version.
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Glossary
4EBP1: Eukaryotic Translation Initiation Factor 4E Binding Protein 1
AIP: Aryl Hydrocarbon Receptor Interacting Protein
AKT: AKT Serine/Threonine Kinase
AP-1: Activator protein 1
ATF-2: Activating Transcription Factor 2
Bcl-XL: Bcl2 Like 1
BMI1: B Lymphoma Mo-MLV Insertion Region 1 Homolog
Cas9: CRISPR associated protein 9
CCNA2: Cyclin A2
CDK4: Cyclin Dependent Kinase 4
CRC: colorectal cancer
CREB: cAMP response element-binding protein
CRISPR: Clustered Regularly Interspaced Short Palindromic Repeats
DLC-1: DLC1 Rho GTPase Activating Protein
E2F1: E2F Transcription Factor 1
eIF4A3: Eukaryotic Translation Initiation Factor 4A3
EMT: epithelial-to-mesenchymal transition
ERK: extracellular signal-regulated kinase
FSCN1: Fascin Actin-Bundling Protein 1
GATA4: GATA Binding Protein 4
GH: growth hormone
GHR: growth hormone receptor
GHRH: Growth Hormone Releasing Hormone
GRB2: Growth Factor Receptor Bound Protein 2
GSK3 α/β: Glycogen Synthase Kinase 3 Alpha and Beta
HMGA1: High Mobility Group AT-Hook 1
HMGA2: High Mobility Group AT-Hook 2
IGF1: Insulin Like Growth Factor 1
IGF2: Insulin Like Growth Factor 2
IGF1R: Insulin Like Growth Factor 1 Receptor
IGF2R: Insulin Like Growth Factor 2 Receptor
IGF2BP3: Insulin Like Growth Factor 2 mRNA Binding Protein 3
IGFBP: Insulin Like Growth Factor Binding Protein
IRS: Insulin Receptor Substrate
JAK: Janus Kinase
JNK: c-Jun N-terminal kinase
KIT: KIT Proto-Oncogene, Receptor Tyrosine Kinase
KRAS: KRAS Proto-Oncogene, GTPase
lncRNA: long non-coding RNA
MAPK: Mitogen-Activated Protein Kinase
MEK1/2: Mitogen-Activated Protein Kinase 1/2
MEN1: Menin 1
miRNA: microRNA
MMP: Matrix Metallopeptidase
mTOR: mammalian target of rapamycin
mTORC1: mTOR Complex 1
NF-Kb: nuclear factor kappa-light-chain-enhancer of activated B cells
p27: protein 27, encoded by CDKN1B Cyclin Dependent Kinase Inhibitor 1B
p38: protein 38 mitogen-activated protein kinase
p57: protein 57, encoded by CDKN1C Cyclin Dependent Kinase Inhibitor 1C
p70: protein 70 S6 Kinase Protein
p90: protein 90 ribosomal S6 kinase
PDCD4: Programmed Cell Death 4
PI3K: phosphoinositide 3-kinase
PIK3R1: Phosphoinositide-3-Kinase Regulatory Subunit 1
pitNETs: Pituitary neuroendocrine tumors
PLAG1: PLAG1 Zinc Finger
PLAGL2: PLAG1 Like Zinc Finger 2
PRLT: prolactin
PTEN: Phosphatase And Tensin Homolog
Pttg1: PTTG1 Regulator Of Sister Chromatid Separation, Securin
Raf1: Raf-1 Proto-Oncogene, Serine/Threonine Kinase
RAS: rat sarcoma protein
RB: retinoblastoma
RUNX2: RUNX Family Transcription Factor 2
SHC: Src Homology 2 Domain-Containing protein
Smad7: SMAD Family Member 7
SOS: Son of sevenless Ras/Rac Guanine Nucleotide Exchange Factor
SSAs: Somatostatin analogues
SSTR2: Somatostatin Receptor 2
STAT: Signal Transducer And Activator Of Transcription
TGCA: The Cancer Genome Atlas
TGFβ: Transforming Growth Factor Beta
TIMP3: Metallopeptidase Inhibitor 3
UTR: untranslated region
VEGF: Vascular Endothelial Growth Factor
YB-1: Y-box binding protein 1
Wnt: wingless integrated
References
1. Boguszewski CL, Boguszewski MC, Kopchick JJ. Growth Hormone, Insulin-Like Growth Factor System and Carcinogenesis. Endokrynol Pol (2016) 67:414–26. doi: 10.5603/EP.a2016.0053
2. Boguszewski CL, Boguszewski MC. Growth Hormone’s Links to Cancer. Endocr Rev (2019) 40:558–74. doi: 10.1210/er.2018-00166
3. Ranke MB, Wit JM. Growth Hormone - Past, Present and Future. Nat Rev Endocrinol (2018) 14:285–300. doi: 10.1038/nrendo.2018.22
4. Harvey S, Martínez-Moreno CG, Luna M, Arámburo C. Autocrine/paracrine Roles of Extrapituitary Growth Hormone and Prolactin in Health and Disease: An Overview. Gen Comp Endocrinol (2015) 220:103–11. doi: 10.1016/j.ygcen.2014.11.004
5. Bergan-Roller HE, Sheridan MA. The Growth Hormone Signalling System: Insights Into Coordinating the Anabolic and Catabolic Actions of Growth Hormone. Gen Comp Endocrinol (2018) 258:119–33. doi: 10.1016/j.ygcen.2017.07.028
6. Steyn FJ, Tolle V, Chen C, Epelbaum J. Neuroendocrine Regulation of Growth Hormone Secretion. Compr Physiol (2016) 6:687–735. doi: 10.1002/cphy.c150002
7. Milman S, Huffman DM, Barzilai N. The Somatotropic Axis in Human Aging: Framework for the Current State of Knowledge and Future Research. Cell Metab (2016) 23:980–9. doi: 10.1016/j.cmet.2016.05.014
8. Brahmkhatri VP, Prasanna C, Atreya HS. Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies. BioMed Res Int (2015) 2015:538019. doi: 10.1155/2015/538019
9. Kasprzak A, Adamek A. Insulin-Like Growth Factor 2 (IGF2) Signaling in Colorectal Cancer-From Basic Research to Potential Clinical Applications. Int J Mol Sci (2019) 20(19):4915. doi: 10.3390/ijms20194915
10. Clemmons DR. Role of IGF-Binding Proteins in Regulating IGF Responses to Changes in Metabolism. J Mol Endocrinol (2018) 61:T139–69. doi: 10.1530/JME-18-0016
11. Bach LA. What Happened to the IGF Binding Proteins? Endocrinology (2018) 159:570–8. doi: 10.1210/en.2017-00908
12. Brittain AL, Basu R, Qian Y, Kopchick JJ. Growth Hormone and the Epithelial-To-Mesenchymal Transition. J Clin Endocrinol Metab (2017) 102:3662–73. doi: 10.1210/jc.2017-01000
13. Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T. Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies. Target Oncol (2017) 12:571–97. doi: 10.1007/s11523-017-0514-5
14. Chesnokova V, Melmed S. Growth Hormone in the Tumour Microenvironment. Arch Endocrinol Metab (2019) 63:568–75. doi: 10.20945/2359-3997000000186
15. Sävendahl L, Cooke R, Tidblad A, Beckers D, Butler G, Cianfarani S, et al. Long-Term Mortality After Childhood Growth Hormone Treatment: The SAGhE Cohort Study. Lancet Diabetes Endocrinol (2020) 8:683–92. doi: 10.1016/S2213-8587(20)30163-7
16. Poidvin A, Carel JC, Ecosse E, Levy D, Michon J, Coste J. Increased Risk of Bone Tumors After Growth Hormone Treatment in Childhood: A Population-Based Cohort Study in France. Cancer Med (2018) 7:3465–73. doi: 10.1002/cam4.1602
17. Carel JC, Ecosse E, Landier F, Meguellati-Hakkas D, Kaguelidou F, Rey G, et al. Long-Term Mortality After Recombinant Growth Hormone Treatment for Isolated Growth Hormone Deficiency or Childhood Short Stature: Preliminary Report of the French SAGhE Study. J Clin Endocrinol Metab (2012) 97:416–25. doi: 10.1210/jc.2011-1995
18. Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, et al. Long-Term Surveillance of Growth Hormone Therapy. J Clin Endocrinol Metab (2012) 97:68–72. doi: 10.1210/jc.2011-2294
19. Yamamoto M, Takahashi Y. Colorectalk Neoplasm in Acromegaly: Epidemiology and Underlying Mechanism in Growth Disorders and Acromegaly. In: Ahmed RG, Ahmet U, editors. London, UK: IntechOpen (2020).
20. Dworakowska D, Grossman AB. Colonic Cancer and Acromegaly. Front Endocrinol (Lausanne) (2019) 10:390. doi: 10.3389/fendo.2019.00390
21. Peng Y, Croce C. The Role of MicroRNAs in Human Cancer. Signal Transduct Target Ther (2016) 1:15004. doi: 10.1038/sigtrans.2015.4
22. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation. Front Endocrinol (Lausanne) (2018) 9:402. doi: 10.3389/fendo.2018.00402
23. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of Post-Transcriptional Regulation by microRNAs: Are the Answers in Sight? Nat Rev Genet (2008) 9:102–14. doi: 10.1038/nrg2290
24. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent Deletions and Down-Regulation of Micro- RNA Genes miR15 and miR16 at 13q14 in Chronic Lymphocytic Leukemia. Proc Natl Acad Sci USA (2002) 99:15524–9. doi: 10.1073/pnas.242606799
25. Di Leva G, Garofalo M, Croce CM. microRNAs in Cancer. Annu Rev Pathol (2014) 9:287–314. doi: 10.1146/annurev-pathol-012513-104715
26. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA Expression Signature of Human Solid Tumours Defines Cancer Gene Targets. Proc Natl Acad Sci USA (2006) 103:2257–61. doi: 10.1073/pnas.0510565103
27. Ravegnini G, Cargnin S, Sammarini G, Zanotti F, Bermejo JL, Hrelia P, et al. Prognostic Role of miR-221 and miR-222 Expression in Cancer Patients: A Systematic Review and Meta-Analysis. Cancers (Basel) (2019) 11:970. doi: 10.3390/cancers11070970
28. Garofalo M, Quintavalle C, Romano G, Croce CM, Condorelli G. miR221/222 in Cancer: Their Role in Tumour Progression and Response to Therapy. Curr Mol Med (2012) 12:27–33. doi: 10.2174/156652412798376170
29. Koelz M, Lense J, Wrba F, Scheffler M, Dienes HP, Odenthal M. Down-Regulation of miR-221 and miR-222 Correlates With Pronounced Kit Expression in Gastrointestinal Stromal Tumours. Int J Oncol (2011) 38:503–11. doi: 10.3892/ijo.2010.857
30. Wang KC, Chang HY. Molecular Mechanisms of Long Noncoding RNAs. Mol Cell (2011) 43:904–14. doi: 10.1016/j.molcel.2011.08.018
31. Cirillo F, Catellani C, Lazzeroni P, Sartori C, Street ME. The Role of microRNAs in Influencing Body Growth and Development. Horm Res Paediatr (2020) 93:7–15. doi: 10.1159/000504669
32. Asa SL, Asioli S, Bozkurt S, Casar-Borota O, Chinezu L, Comunoglu N, et al. Pituitary Neuroendocrine Tumors (PitNETs): Nomenclature Evolution, Not Clinical Revolution. Pituitary (2020) 23:322–5. doi: 10.1007/s11102-019-01015-0
33. Faltermeier CM, Magill ST, Blevins LS Jr, Aghi MK. Molecular Biology of Pituitary Adenomas. Neurosurg Clin N Am (2019) 30:391–400. doi: 10.1016/j.nec.2019.05.001
34. Tatsi C, Stratakis CA. The Genetics of Pituitary Adenomas. J Clin Med (2019) 9:30. doi: 10.3390/jcm9010030
35. Cheng M, Huang W, Cai W, Fang M, Chen Y, Wang C, et al. Growth Hormone Receptor Promotes Osteosarcoma Cell Growth and Metastases. FEBS Open Bio (2020) 10:127–34. doi: 10.1002/2211-5463.12761
36. Tzanakakis GN, Giatagana EM, Berdiaki A, Spyridaki I, Hida K, Neagu M, et al. The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis. Cancers (Basel) (2021) 13:2478. doi: 10.3390/cancers13102478
37. Wang YH, Han XD, Qiu Y, Xiong J, Yu Y, Wang B, et al. Increased Expression of Insulin-Like Growth Factor-1 Receptor Is Correlated With Tumor Metastasis and Prognosis in Patients With Osteosarcoma. J Surg Oncol (2012) 105:235–43. doi: 10.1002/jso.22077
38. Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh Z, Khoudari G, Sarmini MT, et al. Colorectal Cancer Epidemiology: Recent Trends and Impact on Outcomes. Curr Drug Targets (2020) 22(9):998–1009. doi: 10.2174/1389450121999201117115717
39. Desbois-Mouthon C, Cadoret A, Blivet-Van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C, et al. Insulin and IGF-1 Stimulate the Beta-Catenin Pathway Through Two Signalling Cascades Involving GSK-3beta Inhibition and Ras Activation. Oncogene (2001) 20:252–9. doi: 10.1038/sj.onc.1204064
40. Naishiro Y, Yamada T, Takaoka AS, Hayashi R, Hasegawa F, Imai K, et al. Restoration of Epithelial Cell Polarity in a Colorectal Cancer Cell Line by Suppression of Beta-Catenin/T-Cell Factor 4-Mediated Gene Transactivation. Cancer Res (2001) 61:2751–8.
41. Playford MP, Bicknell D, Bodmer WF, Macaulay VM. Insulin-Like Growth Factor 1 Regulates the Location, Stability, and Transcriptional Activity of Beta-Catenin. Proc Natl Acad Sci USA (2000) 97:12103–8. doi: 10.1073/pnas.210394297
42. Manning AM, Williams AC, Game SM, Paraskeva C. Differential Sensitivity of Human Colonic Adenoma and Carcinoma Cells to Transforming Growth Factor Beta (TGF-Beta): Conversion of an Adenoma Cell Line to a Tumorigenic Phenotype Is Accompanied by a Reduced Response to the Inhibitory Effects of TGF-Beta. Oncogene (1991) 6:1471–6.
43. Di Popolo A, Memoli A, Apicella A, Tuccillo C, di Palma A, Ricchi P, et al. IGF-II/IGF-I Receptor Pathway Up-Regulates COX-2 mRNA Expression and PGE2 Synthesis in Caco-2 Human Colon Carcinoma Cells. Oncogene (2000) 19:5517–24. doi: 10.1038/sj.onc.1203952
44. Párrizas M, LeRoith D. Insulin-Like Growth Factor-1 Inhibition of Apoptosis Is Associated With Increased Expression of the bcl-xL Gene Product. Endocrinology (1997) 138:1355–8. doi: 10.1210/endo.138.3.5103
45. Bustin SA, Jenkins PJ. The Growth Hormone-Insulin-Like Growth Factor-I Axis and Colorectal Cancer. Trends Mol Med (2001) 7(10):447–54. doi: 10.1016/s1471-4914(01)02104-9
46. Warren RS, Yuan H, Matli MR, Ferrara N, Donner DB. Induction of Vascular Endothelial Growth Factor by Insulin-Like Growth Factor 1 in Colorectal Carcinoma. J Biol Chem (1996) 271(46):29483–8. doi: 10.1074/jbc.271.46.29483
47. Kasprzak A. Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer. Int J Mol Sci (2021) 22:6434. doi: 10.3390/ijms22126434
48. Fan X, Mao Z, He D, Liao C, Jiang X, Lei N, et al. Expression of Somatostatin Receptor Subtype 2 in Growth Hormone-Secreting Pituitary Adenoma and the Regulation of miR-185. J Endocrinol Invest (2015) 38:1117–28. doi: 10.1007/s40618-015-0306-7
49. Bottoni A, Piccin D, Tagliati F, Luchin A, Zatelli MC, degli Uberti EC. miR-15a and miR-16-1 Down-Regulation in Pituitary Adenomas. J Cell Physiol (2005) 204:280–5. doi: 10.1002/jcp.20282
50. Lines KE, Newey PJ, Yates CJ, Stevenson M, Dyar R, Walls GV, et al. MiR-15a/miR-16-1 Expression Inversely Correlates With Cyclin D1 Levels in Men1 Pituitary NETs. J Endocrinol (2018) 240:41–50. doi: 10.1530/JOE-18-0278
51. Elzein S, Gates Goodyer C. Regulation of Human Growth Hormone Receptor Expression by microRNAs. Mol Endocrinol (2014) 28:1448–59. doi: 10.1210/me.2014-1183
52. D’Angelo D, Palmieri D, Mussnich P, Roche M, Wierinckx A, Raverot G, et al. Altered microRNA Expression Profile in Human Pituitary GH Adenomas: Down-Regulation of miRNA Targeting HMGA1, HMGA2, and E2F1. J Clin Endocrinol Metab (2012) 97:E1128–38. doi: 10.1210/jc.2011-3482
53. Iiritano S, Chiefari E, Ventura V, Arcidiacono B, Possidente K, Nocera A, et al. The HMGA1-IGF-I/IGFBP System: A Novel Pathway for Modulating Glucose Uptake. Mol Endocrinol (2012) 26:1578–89. doi: 10.1210/me.2011-1379
54. Aiello A, Pandini G, Sarfstein R, Werner H, Manfioletti G, Vigneri R, et al. HMGA1 Protein Is a Positive Regulator of the Insulin-Like Growth Factor-I Receptor Gene. Eur J Cancer (2010) 46:1919–26. doi: 10.1016/j.ejca.2010.02.050
55. Trivellin G, Butz H, Delhove J, Igreja S, Chahal HS, Zivkovic V, et al. MicroRNA miR-107 Is Overexpressed in Pituitary Adenomas and Inhibits the Expression of Aryl Hydrocarbon Receptor-Interacting Protein In Vitro. Am J Physiol Endocrinol Metab (2012) 303:E708–19. doi: 10.1152/ajpendo.00546.2011
56. Fukuda T, Tanaka T, Hamaguchi Y, Kawanami T, Nomiyama T, Yanase T. Augmented Growth Hormone Secretion and Stat3 Phosphorylation in an Aryl Hydrocarbon Receptor Interacting Protein (AIP)-Disrupted Somatotroph Cell Line. PloS One (2016) 11:e0164131. doi: 10.1371/journal.pone.0164131
57. Palumbo T, Faucz FR, Azevedo M, Xekouki P, Iliopoulos D, Stratakis CA. Functional Screen Analysis Reveals miR-26b and miR-128 as Central Regulators of Pituitary Somatomammotrophic Tumour Growth Through Activation of the PTEN-AKT Pathway. Oncogene (2013) 32:1651–9. doi: 10.1038/onc.2012.190
58. Leone V, Langella C, D’Angelo D, Mussnich P, Wierinckx A, Terracciano L, et al. Mir-23b and miR-130b Expression Is Downregulated in Pituitary Adenomas. Mol Cell Endocrinol (2014) 390:1–7. doi: 10.1016/j.mce.2014.03.002
59. Li Z, Gilbert JA, Zhang Y, Zhang M, Qiu Q, Ramanujan K, et al. An HMGA2-IGF2BP2 Axis Regulates Myoblast Proliferation and Myogenesis. Dev Cell (2012) 23:1176–88. doi: 10.1016/j.devcel.2012.10.019
60. Dai N, Rapley J, Angel M, Yanik MF, Blower MD, Avruch J. mTOR Phosphorylates IMP2 to Promote IGF2 mRNA Translation by Internal Ribosomal Entry. Genes Dev (2011) 25:1159–72. doi: 10.1101/gad.2042311
61. Gan Y, Li Y, Li T, Shu G, Yin G. CCNA2 Acts as a Novel Biomarker in Regulating the Growth and Apoptosis of Colorectal Cancer. Cancer Manag Res (2018) 10:5113–24. doi: 10.2147/CMAR.S176833
62. Lee YJ, Cho JM, Moon JH, Ku CR, Kim J, Kim SH, et al. Increased miR-338-3p Expression Correlates With Invasiveness of GH-Producing Pituitary Adenomas. Endocrine (2017) 58:184–9. doi: 10.1007/s12020-017-1390-6
63. Zhou C. Pituitary Tumors: Role of Pituitary Tumor-Transforming Gene-1 (Pttg1). In: Hayat M, editor. Tumors of the Central Nervous System. Dordrecht: Springer (2013).
64. He Z, Chen L, Hu X, Tang J, He L, Hu J, et al. Next-Generation Sequencing of microRNAs Reveals a Unique Expression Pattern in Different Types of Pituitary Adenomas. Endocr J (2019) 66:709–22. doi: 10.1507/endocrj.EJ18-0487
65. Mao ZG, He DS, Zhou J, Yao B, Xiao WW, Chen CH, et al. Differential Expression of microRNAs in GH-Secreting Pituitary Adenomas. Diagn Pathol (2010) 5:79. doi: 10.1186/1746-1596-5-79
66. Wu G, Liu J, Wu Z, Wu X, Yao X. MicroRNA-184 Inhibits Cell Proliferation and Metastasis in Human Colorectal Cancer by Directly Targeting IGF-1R. Oncol Lett (2017) 14:3215–22. doi: 10.3892/ol.2017.6499
67. Xiong Y, Tang Y, Fan F, Zeng Y, Li C, Zhou G, et al. Exosomal hsa-miR-21-5p Derived From Growth Hormone-Secreting Pituitary Adenoma Promotes Abnormal Bone Formation in Acromegaly. Transl Res (2020) 215:1–16. doi: 10.1016/j.trsl.2019.07.013
68. Wu ZR, Yan L, Liu YT, Cao L, Guo YH, Zhang Y, et al. Inhibition of mTORC1 by lncRNA H19 Via Disrupting 4E-BP1/Raptor Interaction in Pituitary Tumours. Nat Commun (2018) 9:4624. doi: 10.1038/s41467-018-06853-3
69. Lu T, Yu C, Ni H, Liang W, Yan H, Jin W. Expression of the Long Non-Coding RNA H19 and MALAT-1 in Growth Hormone-Secreting Pituitary Adenomas and its Relationship to Tumour Behavior. Int J Dev Neurosci (2018) 67:46–50. doi: 10.1016/j.ijdevneu.2018.03.009
70. Mezzomo LS, Gonzales PH, Giacomoni Pesce F, Kretzmann Filho N, Pires Ferreira N, Costa Oliveira M, et al. Expression of Cell Growth Negative Regulators MEG3 and GADD45γ Is Lost in Most Sporadic Human Pituitary Adenomas. Pituitary (2012) 15:420–7. doi: 10.1007/s11102-011-0340-
71. Tang C, Zhong C, Cong Z, Yang J, Wen G, Zhu J, et al. MEG3 Is Associated With Gsp Oncogene Regulation of Growth Hormone Hypersecretion, Proliferation and Invasiveness of Human GH-Secreting Adenomas. Oncol Lett (2019) 17:3495–502. doi: 10.3892/ol.2019.10006
72. D’Angelo D, Esposito F, Fusco A. Epigenetic Mechanisms Leading to Overexpression of HMGA Proteins in Human Pituitary Adenomas. Front Med (Lausanne) (2015) 2:39. doi: 10.3389/fmed.2015.00039
73. Zhou C, Jiao Y, Wang R, Ren SG, Wawrowsky K, Melmed S. STAT3 Upregulation in Pituitary Somatotroph Adenomas Induces Growth Hormone Hypersecretion. J Clin Invest (2015) 125:1692–702. doi: 10.1172/JCI78173
74. Carter-Su C, Schwartz J, Argetsinger LS. Growth Hormone Signaling Pathways. Growth Horm IGF Res (2016) 28:11–5. doi: 10.1016/j.ghir.2015.09.002
75. Ren SG, Kim S, Taylor J, Dong J, Moreau JP, Culler MD, et al. Suppression of Rat and Human Growth Hormone and Prolactin Secretion by a Novel Somatostatin/Dopaminergic Chimeric Ligand. J Clin Endocrinol Metab (2003) 88:5414–21. doi: 10.1210/jc.2003-030302
76. Tan X, Fan S, Wu W, Zhang Y. MicroRNA-26a Inhibits Osteosarcoma Cell Proliferation by Targeting IGF-1. Bone Res (2015) 3:15033. doi: 10.1038/boneres.2015.33
77. Chen L, Wang Q, Wang GD, Wang HS, Huang Y, Liu XM, et al. miR-16 Inhibits Cell Proliferation by Targeting IGF1R and the Raf1-MEK1/2-ERK1/2 Pathway in Osteosarcoma. FEBS Lett (2013) 587:1366–72. doi: 10.1016/j.febslet.2013.03.007
78. Liu Y, Zhu ST, Wang X, Deng J, Li WH, Zhang P, et al. MiR-100 Inhibits Osteosarcoma Cell Proliferation, Migration, and Invasion and Enhances Chemosensitivity by Targeting IGFIR. Technol Cancer Res Treat (2016) 15:NP40–8. doi: 10.1177/1533034615601281
79. Chen G, Fang T, Huang Z, Qi Y, Du S, Di T, et al. MicroRNA-133a Inhibits Osteosarcoma Cells Proliferation and Invasion Via Targeting IGF-1R. Cell Physiol Biochem (2016) 38:598–608. doi: 10.1159/000438653
80. Wang Z, Zheng C, Jiang K, He J, Cao X, Wu S. MicroRNA-503 Suppresses Cell Proliferation and Invasion in Osteosarcoma Via Targeting Insulin-Like Growth Factor 1 Receptor. Exp Ther Med (2017) 14:1547–53. doi: 10.3892/etm.2017.4648
81. Zhang C, Song G, Ye G, Xu B. MicroRNA-302a Inhibits Osteosarcoma Cell Migration and Invasion by Directly Targeting IGF-1R. Oncol Lett (2018) 15:5577–83. doi: 10.3892/ol.2018.8049
82. Zhao X, Li J, Yu D. MicroRNA-939-5p Directly Targets IGF-1R to Inhibit the Aggressive Phenotypes of Osteosarcoma Through Deactivating the PI3K/Akt Pathway. Int J Mol Med (2019) 44:1833–43. doi: 10.3892/ijmm.2019.4333
83. Li C, Zhang S, Qiu T, Wang Y, Ricketts DM, Qid C. Upregulation of Long Non-Coding RNA NNT-AS1 Promotes Osteosarcoma Progression by Inhibiting the Tumour Suppressive miR-320a. Cancer Biol Ther (2019) 20:413–22. doi: 10.1080/15384047.2018.1538612
84. Xu N, Xu J, Zuo Z, Liu Y, Yan F, Han C. Downregulation of lncRNA SNHG12 Reversed IGF1R-Induced Osteosarcoma Metastasis and Proliferation by Targeting miR-195-5p. Gene (2020) 726:144145. doi: 10.1016/j.gene.2019.144145
85. Fei D, Zhang X, Lu Y, Tan L, Xu M, Zhang Y. Long Noncoding RNA AFAP1-AS1 Promotes Osteosarcoma Progression by Regulating miR-497/IGF1R Axis. Am J Transl Res (2020) 12:2155–68. doi: 10.1038/s41419-021-03917-z
86. Knowlton DL, Tang K, Henstock PV, Subramanian RR. miRNA Alterations Modify Kinase Activation In The IGF-1 Pathway And Correlate With Colorectal Cancer Stage And Progression In Patients. J Cancer (2011) 2:490–502. doi: 10.7150/jca.2.490
87. Su J, Liang H, Yao W, Wang N, Zhang S, Yan X, et al. MiR-143 and MiR-145 Regulate IGF1R to Suppress Cell Proliferation in Colorectal Cancer. PloS One (2014) 9:e114420. doi: 10.1371/journal.pone.0114420
88. Josse C, Bouznad N, Geurts P, Irrthum A, Huynh-Thu VA, Servais L, et al. Identification of a microRNA Landscape Targeting the PI3K/Akt Signalling Pathway in Inflammation-Induced Colorectal Carcinogenesis. Am J Physiol Gastrointest Liver Physiol (2014) 306:G229–43. doi: 10.1152/ajpgi.00484.2012
89. Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, et al. MiR-139 Inhibits Invasion and Metastasis of Colorectal Cancer by Targeting the Type I Insulin-Like Growth Factor Receptor. Biochem Pharmacol (2012) 84:320–30. doi: 10.1016/j.bcp.2012.04.017
90. Guo ST, Jiang CC, Wang GP, Li YP, Wang CY, Guo XY, et al. MicroRNA-497 Targets Insulin-Like Growth Factor 1 Receptor and has a Tumour Suppressive Role in Human Colorectal Cancer. Oncogene (2013) 32:1910–20. doi: 10.1038/onc.2012.214
91. Chu PC, Lin PC, Wu HY, Lin KT, Wu C, Bekaii-Saab T, et al. Mutant KRAS Promotes Liver Metastasis of Colorectal Cancer, in Part, by Upregulating the MEK-Sp1-DNMT1-miR-137-YB-1-IGF-IR Signalling Pathway. Oncogene (2018) 37:3440–55. doi: 10.1038/s41388-018-0222-3
92. Song Y, Zhao Y, Ding X, Wang X. microRNA-532 Suppresses the PI3K/Akt Signalling Pathway to Inhibit Colorectal Cancer Progression by Directly Targeting IGF-1R. Am J Cancer Res (2018) 8:435–49.
93. Li Z, Pan W, Shen Y, Chen Z, Zhang L, Zhang Y, et al. IGF1/IGF1R and microRNA Let-7e Down-Regulate Each Other and Modulate Proliferation and Migration of Colorectal Cancer Cells. Cell Cycle (2018) 17:1212–9. doi: 10.1080/15384101.2018.1469873
94. Samadi P, Afshar S, Amini R, Najafi R, Mahdavinezhad A, Sedighi Pashaki A, et al. Let-7e Enhances the Radiosensitivity of Colorectal Cancer Cells by Directly Targeting Insulin-Like Growth Factor 1 Receptor. J Cell Physiol (2019) 234:10718–25. doi: 10.1002/jcp.27742
95. Chen YC, Ou MC, Fang CW, Lee TH, Tzeng SL. High Glucose Concentrations Negatively Regulate the IGF1R/Src/ERK Axis Through the microRNA-9 in Colorectal Cancer. Cells (2019) 8:326. doi: 10.3390/cells8040326
96. Medlej A, Mohammad Soltani B, Javad Mowla S, Hosseini S, Baharvand H. A Novel miRNA Located in the GATA4 Gene Regulates the Expression of IGF-1R and AKT1/2 Genes and Controls Cell Proliferation. J Cell Biochem (2020) 121:3438–50. doi: 10.1002/jcb.29617
97. Tsang WP, Ng EKO, Ng SSM, Jin H, Yu J, Sung JJY, et al. Oncofetal H19-Derived miR-675 Regulates Tumour Suppressor RB in Human Colorectal Cancer. Carcinogenesis (2010) 31:350–8. doi: 10.1093/carcin/bgp181
98. Ghafouri-Fard S, Esmaeili M, Taheri M. H19 lncRNA: Roles in Tumorigenesis. BioMed Pharmacother (2020) 123:109774. doi: 10.1016/j.biopha.2019.109774
99. Keniry A, Oxley D, Monnier P, Kyba M, Dandolo L, Smits G, et al. The H19 lincRNA Is a Developmental Reservoir of miR-675 That Suppresses Growth and Igf1r. Nat Cell Biol (2012) 14:659–65. doi: 10.1038/ncb2521
100. Cui H, Liu Y, Jiang J, Liu Y, Yang Z, Wu S, et al. IGF2-Derived miR-483 Mediated Oncofunction by Suppressing DLC-1 and Associated With Colorectal Cancer. Oncotarget (2016) 7:48456–66. doi: 10.18632/oncotarget.10309
101. Liu X, Chen X, Zeng K, Xu M, He B, Pan Y, et al. DNA-Methylation-Mediated Silencing of miR-486-5p Promotes Colorectal Cancer Proliferation and Migration Through Activation of PLAGL2/IGF2/β-Catenin Signal Pathways. Cell Death Dis (2018) 9:1037. doi: 10.1038/s41419-018-1105-9
102. Shi L, Li X, Wu Z, Li X, Nie J, Guo M, et al. DNA Methylation-Mediated Repression of miR-181a/135a/302c Expression Promotes the Microsatellite-Unstable Colorectal Cancer Development and 5-FU Resistance Via Targeting PLAG1. J Genet Genomics (2018) 45:205–14. doi: 10.1016/j.jgg.2018.04.003
103. Lu L, Cai M, Peng M, Wang F, Zhai X. miR-491-5p Functions as a Tumour Suppressor by Targeting IGF2 in Colorectal Cancer. Cancer Manag Res (2019) 11:1805–16. doi: 10.2147/CMAR.S183085
104. Ellis BC, Graham LD, Molloy PL. CRNDE, a Long Non-Coding RNA Responsive to Insulin/IGF Signalling, Regulates Genes Involved in Central Metabolism. Biochim Biophys Acta (2014) 1843:372–86. doi: 10.1016/j.bbamcr.2013.10.016
105. Han D, Gao X, Wang M, Qiao Y, Xu Y, Yang J, et al. Long Noncoding RNA H19 Indicates a Poor Prognosis of Colorectal Cancer and Promotes Tumour Growth by Recruiting and Binding to eIF4A3. Oncotarget (2016) 7:22159–73. doi: 10.18632/oncotarget.8063
106. Yang Q, Wang X, Tang C, Chen X, He J. H19 Promotes the Migration and Invasion of Colon Cancer by Sponging miR-138 to Upregulate the Expression of HMGA1. Int J Oncol (2017) 50:1801–9. doi: 10.3892/ijo.2017.3941
107. Zhang X, Li H, Burnett JC, Rossi JJ. The Role of Antisense Long Noncoding RNA in Small RNA-Triggered Gene Activation. RNA (2014) 20:1916–28. doi: 10.1261/rna.043968.113
108. Liang Y, Zhang C, Ma M, Dai D. Identification and Prediction of Novel Non-Coding and Coding RNA-Associated Competing Endogenous RNA Networks in Colorectal Cancer. World J Gastroenterol (2018) 24:5259–70. doi: 10.3748/wjg.v24.i46.5259
109. Yang Y, Zhao Y, Zhang W, Bai Y. Whole Transcriptome Sequencing Identifies Crucial Genes Associated With Colon Cancer and Elucidation of Their Possible Mechanisms of Action. Onco Targets Ther (2019) 12:2737–47. doi: 10.2147/OTT.S195235
110. Balaguer F, Moreira L, Lozano JJ, Link A, Ramirez G, Shen Y, et al. Colorectal Cancers With Microsatellite Instability Display Unique miRNA Profiles. Clin Cancer Res (2011) 17:6239–49. doi: 10.1158/1078-0432.CCR-11-1424
111. Mizuno R, Kawada K, Sakai Y. The Molecular Basis and Therapeutic Potential of Let-7 MicroRNAs Against Colorectal Cancer. Can J Gastroenterol Hepatol (2018) 2018:5769591. doi: 10.1155/2018/5769591
112. Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, et al. Epigenetic Regulation of microRNA Expression in Colorectal Cancer. Int J Cancer (2009) 125:2737–43. doi: 10.1002/ijc.24638
113. Zhu M, Xu Y, Ge M, Gui Z, Yan F. Regulation of UHRF1 by microRNA-9 Modulates Colorectal Cancer Cell Proliferation and Apoptosis. Cancer Sci (2015) 106:833–9. doi: 10.1111/cas.12689
114. Van Dyck F, Declercq J, Braem CV, Van de Ven WJM. PLAG1, the Prototype of the PLAG Gene Family: Versatility in Tumour Development (Review). Int J Oncol (2007) 30:765–74. doi: 10.3892/ijo.30.4.765
115. Beylerli O, Gareev I, Pavlov V, Chen X, Zhao S. The Role of Long Noncoding RNAs in the Biology of Pituitary Adenomas. World Neurosurg (2020) 137:252–6. doi: 10.1016/j.wneu.2019.10.137
116. Hayashi AA, Proud CG. The Rapid Activation of Protein Synthesis by Growth Hormone Requires Signalling Through mTOR. Am J Physiol Endocrinol Metab (2007) 292:E1647–55. doi: 10.1152/ajpendo.00674.2006
117. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, et al. A Pituitary-Derived MEG3 Isoform Functions as a Growth Suppressor in Tumor Cells. J Clin Endocrinol Metab (2003) 88:5119–26. doi: 10.1210/jc.2003-030222
118. Graham LD, Pedersen SK, Brown GS, Ho T, Kassir Z, Moynihan AT, et al. Colorectal Neoplasia Differentially Expressed (CRNDE), a Novel Gene With Elevated Expression in Colorectal Adenomas and Adenocarcinomas. Genes Cancer (2011) 2:829–40. doi: 10.1177/1947601911431081
119. Sasaki H, Ishihara K, Kato R. Mechanisms of Igf2/H19 Imprinting: DNA Methylation, Chromatin and Long-Distance Gene Regulation. J Biochem (2000) 127:711–5. doi: 10.1093/oxfordjournals.jbchem.a022661
120. Dai L, Li J, Dong Z, Liu Y, Chen Y, Chen N, et al. Temporal Expression and Functional Analysis of Long Non-Coding RNAs in Colorectal Cancer Initiation. J Cell Mol Med (2019) 23:4127–38. doi: 10.1111/jcmm.14300
121. Zhang Z, Qian W, Wang S, Ji D, Wang Q, Li J, et al. Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma. Cell Physiol Biochem (2018) 49:1778–91. doi: 10.1159/000493623
Keywords: GH, IGF, miRNA, lncRNA, cancer
Citation: Catellani C, Ravegnini G, Sartori C, Angelini S and Street ME (2021) GH and IGF System: The Regulatory Role of miRNAs and lncRNAs in Cancer. Front. Endocrinol. 12:701246. doi: 10.3389/fendo.2021.701246
Received: 27 April 2021; Accepted: 13 July 2021;
Published: 16 August 2021.
Edited by:
Veronica Vella, University of Catania, ItalyReviewed by:
Joseph A. M. J. L. Janssen, Erasmus University Rotterdam, NetherlandsChuzhong Li, Capital Medical University, China
Copyright © 2021 Catellani, Ravegnini, Sartori, Angelini and Street. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria E. Street, mariaelisabeth.street@ausl.re.it